Titan Pharmaceuticals And Molteni Receive European Regulatory Approval For Probuphine
(WorldNews Health)

SOUTH SAN FRANCISCO, Calif., June 26, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the European Commission (`EC`) has approved Sixmo®-buprenorphine, the brand name for Probuphine® (buprenorphine) implant in the European Union (`EU`). The EC`s decision, received today by Molteni, applies to all 28 EU member states, where Sixmo is now approved for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment. `This is a major milestone for us as well as for our commercialization partner, Molteni, and we are...